AbbVie Inc. (ETR:4AB)
Germany
· Delayed Price · Currency is EUR | Market Cap | 332.21B |
| Revenue (ttm) | 54.41B |
| Net Income (ttm) | 4.09B |
| Shares Out | n/a |
| EPS (ttm) | 2.31 |
| PE Ratio | 81.16 |
| Forward PE | n/a |
| Dividend | 5.88 (3.13%) |
| Ex-Dividend Date | Apr 15, 2025 |
| Volume | 515 |
| Average Volume | 711 |
| Open | 188.40 |
| Previous Close | 187.36 |
| Day's Range | 186.64 - 188.70 |
| 52-Week Range | 141.98 - 204.45 |
| Beta | 0.60 |
| RSI | 43.81 |
| Earnings Date | Apr 25, 2025 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial numbers in USD Financial StatementsNews
AbbVie shares rose after seven consecutive sessions of losses
Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.
Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-...
AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025
Data for ABBV-969, a novel STEAP1/PSMA dual-targeted antibody-drug conjugate (ADC) in Phase 1 for advanced prostate cancer, will be presented in an oral presentation. Data to be presented on ABBV-514,...
Smart Money Is Betting Big In ABBV Options
Investors with significant funds have taken a bearish position in AbbVie (NYSE: ABBV), a development that retail traders should be aware of. This was brought to our attention today through our monito...
AbbVie Inc (ABBV) Showcases Innovation and Patient-Centric Approach at AMWC 2025
AbbVie Inc (ABBV) Showcases Innovation and Patient-Centric Approach at AMWC 2025
Is AbbVie Gaining or Losing Market Support?
AbbVie's (NYSE: ABBV) short percent of float has fallen 5.41% since its last report. The company recently reported that it has 18.51 million shares sold short , which is 1.05% of all regular shares t...
2025 Dividend Kings: Strong Run Continues
The Dividend Kings are outperforming the S&P 500 in 2025 by 4.57%. Top performers include National Fuel & Gas (+30.21%), Consolidated Edison (+22.66%), and AbbVie (+20.40%). Promising Dividend Kings i...
Enigma Biomedical USA, Inc. Announces Candidate Selection of Novel 4R Tau PET Imaging Biomarkers
KNOXVILLE, Tenn. — Enigma Biomedical USA, Inc. (EB USA) today announced that it has selected two (2) four-repeat tau (4R Tau) protein PET imaging biomarkers to advance into Phase 1 (Ph1) studies. Prev...
My Dividend Stock Portfolio: New February Dividend Record - 100 Holdings With 11 Buys
February investments fell below $1,000, mainly in BDCs like Owl Rock Capital and Ares Capital, boosting annual dividend income by $77. Dividend income hit a new February record of $505, up 5% Y/Y driv...
Here's How Many Shares of AbbVie You Need to Own to Get $1,000 in Yearly Dividends
Multiple Myeloma Market to Witness Substantial Growth -- Key Trends and Forecasts of Different Reports for the Next Decade | DelveInsight
The multiple myeloma market is expected to grow in the upcoming years, owing to a rise in incident cases, label expansion and penetration of current therapies in earlier lines, high adoption of newer ...
Widely used drugs on US imports list from Europe
Widely used prescription medicines could get caught up in the Trump administration's tariff trade wars and EU retaliation.
AbbVie's Elahere Cuts Death Risk By 32%, Shows Consistent Survival Benefit In Long-Term Analysis For Certain Ovarian Cancer Patients
AbbVie's Elahere maintains strong efficacy in the ... Full story available on Benzinga.com
ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients
Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha (FRα)-positi...
Drugmakers agree to participate in second round of price negotiations
All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals , whose medicines are part of the second round of price talks have agreed to participate in the negotiation process, a federal h...
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
Calls of the Day: United Airlines, Delta, IBM, Abbvie, Uber
The Investment Committee debate the latest Calls of the Day.
Calls of the Day: United Airlines, Delta, IBM, Abbvie, Uber
The Investment Committee debate the latest Calls of the Day.
Stocks beating the stock market's recent Trump slump have this in common
This year's top performer among the S&P 500 has been CVS Health's stock, which had a bad 2024 and is cheap by a key valuation measure.
AbbVie Inc. (ABBV) Leerink Partners Global Healthcare Conference (Transcript)
Siri & Glimstad Defeats AbbVie's Motion to Dismiss Illinois GIPA Lawsuit
Call to Action: Join Open Class Action Against AbbVie CHICAGO, IL / ACCESS Newswire / March 11, 2025 / Recently, the Northern District of Illinois denied AbbVie's motion to dismiss a lawsuit alleging ...
MD&M West Celebrates 40 Years of Leadership in Manufacturing Showcasing AI, Sustainability and the Future of MedTech
Top attending companies include Edwards Lifesciences, Mattel, Apple, Medtronic and Abbot/Abbvie. ANAHEIM, CA / ACCESS Newswire / March 10, 2025 / MD&M West, a legacy leader in manufacturing excellence...
Notable healthcare headlines for the week: Walgreens Boots Alliance, AbbVie and Novo Nordisk in focus
Markets faced turbulence as healthcare stocks led gains and losses on Wall Street.
Darst's Stock Picks: GOLD, EL, ABBV
"We currently advise gradually shifting exposure away from high-growth areas toward more value and defensive sectors," notes David Darst. He discusses finding opportunities in an uncertain market.
AbbVie Options Trading: A Deep Dive into Market Sentiment
Whales with a lot of money to spend have taken a noticeably bullish stance on AbbVie . Looking at options history for AbbVie (NYSE: ABBV) we detected 29 trades. If we consider the specifics of each t...